Irritable bowel syndrome and diet

Gastroenterology Report

Volumn 5, Issue 1, 2017, Pages 11-19

  Portincasa, Piero ^a   Bonfrate, Leonilde ^a   De Bari, Ornella ^a   Lembo, Anthony ^b   Ballou, Sarah ^b  

^a UNIVERSITY OF BARI   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

FODMAPs; food; functional gastrointestinal disorders; intestinal microbiota; intolerance; irritable bowel syndrome

Indexed keywords

CURCUMIN; DISACCHARIDE; FENNEL OIL; FRUCTOSE; GLUTEN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTOSE; MESALAZINE; MONOSACCHARIDE; NUTRACEUTICAL; OLIGOSACCHARIDE; PLACEBO; POLYOL; SALAZOSULFAPYRIDINE; SUCROSE; TUMOR NECROSIS FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANXIETY; CLINICAL TRIAL (TOPIC); DIET RESTRICTION; DIET THERAPY; DIETARY FIBER; DIETARY INTAKE; DRUG DOSE COMPARISON; DRUG STRUCTURE; GASTROINTESTINAL MOTILITY; GLUTEN FREE DIET; HUMAN; INTESTINE MUSCLE; IRRITABLE COLON; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; NONHUMAN; PATIENT EDUCATION; PSYCHOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REASSURANCE; REVIEW; SMOOTH MUSCLE RELAXATION; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; ULCERATIVE COLITIS; VISCERAL PAIN;

EID: 85026915240     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gow047     Document Type: Review

References (123)

1. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
2. Lovell RM and Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: A meta-analysis. Clin Gastroenterol Hepatol 2012;10:712-21.e4.
3. Halder SL, Locke GR, 3rd, Schleck CD et al. Natural history of functional gastrointestinal disorders: A 12-year longitudinal population-based study. Gastroenterology 2007;133:799-807.
4. FordAC, FormanD, BaileyAGet al. Irritable bowel syndrome: A 10-yr natural history of symptoms and factors that influence consultation behavior. AmJ Gastroenterol 2008;103:1229-39.
5. Bharadwaj S, Barber MD, Graff LA, et al. Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle. Gastroenterol Rep (Oxf) 2015; 3:185-93.
6. Camilleri M, Heading RC and Thompson WG. Consensus report: Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment.Pharmacol Ther 2002;16:1407-30.
7. Drossman DA, Camilleri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
8. Peery AF, Dellon ES, Lund J et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-87.e1-3.
9. Mearin F, Lacy BE, Chang L et al. Bowel Disorders. Gastroenterology 2016;150:1393-407.e5.
10. Heaton KW and O'Donnell LJD. An Office Guide to Whole-Gut Transit Time. J Clin Gastroenterol 1994;19:28-30.
11. Lewis SJ and Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4.
12. Patel P, Bercik P, Morgan DG et al. Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: Cross-sectional survey. Scand J Gastroenterol 2015;50:816-23.
13. Camilleri M, Lasch K and Zhou W. Irritable bowel syndrome: Methods, mechanisms, and pathophysiology: The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:G775-85.
14. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012;367:1626-35.
15. Bonfrate L, Tack J, Grattagliano I et al. Microbiota in health and irritable bowel syndrome: Current knowledge, perspectives and therapeutic options. Scand J Gastroenterol 2013;48:995-1009.
16. Whitehead WE, Holtkotter B, Enck P et al. Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990;98:1187-92.
17. Bouin M, Plourde V, Boivin M et al. Rectal distention testing in patients with irritable bowel syndrome: Sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002;122:1771-7.
18. Zuo XL, Li YQ, Shi L et al. Visceral hypersensitivity following cold water intake in subjects with irritable bowel syndrome. J Gastroenterol 2006;41:311-7.
19. Nozu T, Kudaira M, Kitamori S et al. Repetitive rectal painful distention induces rectal hypersensitivity in patients with irritable bowel syndrome. J Gastroenterol 2006;41:217-22.
20. Schmidt T, Hackelsberger N, Widmer R et al. Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 1996;31:581-9.
21. Kumar D and Wingate D. Irritable bowel syndrome: A paroxysmal motor disorder. Lancet 1986;1:620-1.
22. Simren M, Castedal M, Svedlund J et al. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS) [correction of (IBD)]. Dig Dis Sci 2000;45:2151-61.
23. Portincasa P, Moschetta A, Baldassarre G et al. Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting the Rome II criteria for irritable bowel. World J Gastroenterol 2003;9:2293-9.
24. Marshall JK, Thabane M, Borgaonkar MR et al. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007;5:457-60.
25. Marshall JK, Thabane M, Garg AX et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006;131:445-50.
26. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:535-44.
27. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome-a meta-analysis. Am J Gastroenterol 2006;101:1894-9.
28. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83.
29. Liebregts T, Adam B, Bredack C et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20.
30. Saito YA, Petersen GM, Locke GR, 3rd et al. The genetics of irritable bowel syndrome. Clin Gastroenterol Hepatol 2005;3:1057-65.
31. Beyder A, Mazzone A, Strege PR et al. Loss-of-function of the voltage-gated sodium channel NaV1.5 (Channelopathies) in patients with irritable bowel syndrome. Gastroenterology 2014;146:1659-68.
32. Chang L. The role of stress on physiological responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011;140:761.
33. Drossman DA, McKee DC, Sandler RS et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988;95:701-8.
34. Francis CY, Morris J and Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
35. Mans JJ, von Lackum K, Dorsey C et al. The degree of microbiome complexity influences the epithelial response to infection. BMC Genomics 2009;10:380.
36. Bonfrate L, Krawczyk M, Lembo A et al. Effects of dietary education, followed by a tailored fructose-restricted diet in adults with fructose malabsorption. Eur J Gastroenterol Hepatol 2015;27:785-96.
37. Gasbarrini A, Corazza GR, Gasbarrini G et al. Methodology and indications of H2-breath testing in gastrointestinal diseases: The Rome Consensus Conference. Aliment Pharmacol Ther 2009;29 Suppl 1:1-49.
38. Ridlon JM, Kang DJ and Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006;47:241-59.
39. Lefebvre P, Cariou B, Lien F et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147-91.
40. Begley M, Gahan CGM and Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005;29:625-51.
41. Wong JMW, de Souza R, Kendall CWC et al. Colonic health: Fermentation and short chain fatty acids. J Clin Gastroenterol 2006;40:235-43.
42. Hijova E and Chmelarova A. Short chain fatty acids and colonic health. Bratisl Lek Listy 2007;108:354-8.
43. Chen WJ, Anderson JW and Jennings D. Propionate may mediate the hypocholesterolemic effects of certain soluble plant fibers in cholesterol-fed rats. Proc Exp Biol Med 1984;175:215-8.
44. Lynch SV, Phimister EG and Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med 2016;375:2369-79.
45. Arora T and Bäckhed F. The gut microbiota and metabolic disease: Current understanding and future perspectives. J Intern Med 2016;280:339-49.
46. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007;133:24-33.
47. Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-82.
48. Rajilic-Stojanovic M, Biagi E, Heilig HG et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011;141:1792-801.
49. Saulnier DM, Riehle K, Mistretta TA et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011;141:1782-91.
50. Jeffery IB, O'Toole PW, Ohman L et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012;61:997-1006.
51. Matto J, Maunuksela L, Kajander K et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005;43:213-22.
52. Maukonen J, Satokari R, Mättö J et al. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006;55:625-33.
53. Codling C, O'Mahony L, Shanahan F et al. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010;55:392-7.
54. Rajilić-Stojanović M, Smidt H and De Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 2007;9:2125-36.
55. Lyra A, Rinttilä T, Nikkilä J et al. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 2009;15:5936-45.
56. Bischoff SC, Barbara G, Buurman W et al. Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterology 2014;14:1-25.
57. Simren M, Barbara G, Flint HJ et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut 2013;62:159-76.
58. Vazquez-Roque MI, Camilleri M, Smyrk T et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: Effects on bowel frequency and intestinal function. Gastroenterology 2013;144:903-11.e3.
59. Ford AC, Moayyedi P, Lacy BE et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 Suppl 1:S2-26.
60. Menees SB, Kurlander J, Goel A et al. Sa1079 A Meta-Analysis of the Utility of Common Serum and Fecal Biomarkers in Adults With IBS. Gastroenterology 2014;146:S-194.
61. Portincasa P, Di Ciaula A, Vacca M et al. Beneficial effects of oral tilactase on patients with hypolactasia. Eur J Clin Invest 2008;38:835-44.
62. Kaptchuk TJ, Kelley JM, Conboy LA et al. Components of placebo effect: Randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008;336:999-1003.
63. Drossman DA and Thompson WG. The irritable bowel syndrome: Review and a graduated multicomponent treatment approach. Ann Intern Med 1992;116:1009-16.
64. Owens DM, Nelson DK and Talley NJ. The irritable bowel syndrome: Long-term prognosis and the physician-patient interaction. Ann Intern Med 1995;122:107-12.
65. Halpert A, Dalton CB, Palsson O et al. Irritable bowel syndrome patients' ideal expectations and recent experiences with healthcare providers: A national survey. Dig Dis Sci 2010;55:375-83.
66. Johannesson E, Simren M, Strid H et al. Physical activity improves symptoms in irritable bowel syndrome: A randomized controlled trial. Am J Gastroenterol 2011;106:915-22.
67. Bijkerk CJ, de Wit NJ, Stalman WA et al. Irritable bowel syndrome in primary care: The patients' and doctors' views on symptoms, etiology and management. Can J Gastroenterol 2003;17:363-8.
68. Simren M, Mansson A, Langkilde AM et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001;63:108-15.
69. Monsbakken KW, Vandvik PO and Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome-etiology, prevalence and consequences. Eur J Clin Nutr 2006;60:667-72.
70. Atkinson W, Sheldon TA, Shaath N et al. Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial. Gut 2004;53:1459-64.
71. Gibson PR. Food intolerance in functional bowel disorders. J Gastroenterol Hepatol 2011;26 Suppl 3:128-31.
72. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94.
73. Raithel M, Baenkler HW, Naegel A et al. Significance of salicylate intolerance in diseases of the lower gastrointestinal tract. J Physiol Pharmacol 2005;56 Suppl 5:89-102.
74. Bijkerk CJ, de Wit NJ, Muris JW et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care?. Randomised placebo controlled trial. BMJ 2009;339:b3154.
75. Rao SS, Yu S and Fedewa A. Systematic review: Dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther 2015;41:1256-70.
76. Drossman DA, Whitehead WE and Camilleri M. Irritable bowel syndrome: A technical review for practice guideline development. Gastroenterology 1997;112:2120-37.
77. Ford AC and Talley NJ. Irritable bowel syndrome. BMJ 2012;345:e5836.
78. Ruepert L, Quartero AO, de Wit NJ et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011:CD003460.
79. Ford AC, Talley NJ, Spiegel BM et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: Systematic review and meta-analysis. BMJ 2008;337:a2313.
80. Zhu Y, Zheng X, Cong Y et al. Bloating and distention in irritable bowel syndrome: The role of gas production and visceral sensation after lactose ingestion in a population with lactase deficiency. Am J Gastroenterol 2013;108:1516-25.
81. Shepherd SJ, Lomer MC and Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 2013;108:707-17.
82. Ong DK, Mitchell SB, Barrett JS et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010;25:1366-73.
83. Gibson PR and Shepherd SJ. Personal view: Food for thought-western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005;21:1399-409.
84. Halmos EP, Power VA, Shepherd SJ et al. A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome. Gastroenterology 2014;146:67-75.e5.
85. Moayyedi P, Quigley EM, Lacy BE et al. The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. Clin Transl Gastroenterol 2015;6:e107.
86. Shepherd SJ, Parker FC, Muir JG et al. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: Randomized placebo-controlled evidence. Clin Gastroenterol Hepatol 2008;6:765-71.
87. Bohn L, Storsrud S, Liljebo T et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: A randomized controlled trial. Gastroenterology 2015;149:1399-407.e2.
88. McKenzie YA, Alder A, Anderson W et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012;25:260-74.
89. Krawczyk M, Wolska M, Schwartz S et al. Concordance of genetic and breath tests for lactose intolerance in a tertiary referral centre. J Gastrointestin Liver Dis 2008;17:135-9.
90. Yang J, Deng Y, Chu H et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2013;11:262-8.e1.
91. American College of Gastroenterology Task Force on Irritable Bowel Syndrome; Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 Suppl 1:S1-35.
92. Bohmer CJ and Tuynman HA. The effect of a lactoserestricted diet in patients with a positive lactose tolerance test, earlier diagnosed as irritable bowel syndrome: A 5-year follow-up study. Eur J Gastroenterol Hepatol 2001;13:941-4.
93. Gray GM, Conklin KA and Townley RR. Sucrase-isomaltase deficiency. Absence of an inactive enzyme variant. N Engl J Med 1976;294:750-3.
94. Peterson ML and Herber R. Intestinal sucrase deficiency. Trans Assoc Am Physicians 1967;80:275-83.
95. Ament ME, Perera DR and Esther LJ. Sucrase-isomaltase deficiency-a frequently misdiagnosed disease. J Pediatr 1973;83:721-7.
96. Choi YK, Johlin FC Jr, Summers RW et al. Fructose intolerance: An under-recognized problem. Am J Gastroenterol 2003;98:1348-53.
97. Choi YK, Kraft N, Zimmerman B et al. Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol 2008;42:233-8.
98. Verdu EF, Huang X, Natividad J et al. Gliadin-dependent neuromuscular and epithelial secretory responses in gluten-sensitive HLA-DQ8 transgenic mice. Am J Physiol Gastrointest Liver Physiol 2008;294:G217-25.
99. Biesiekierski JR, Newnham ED, Irving PM et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011;106:508-14.
100. Biesiekierski JR, Peters SL, Newnham ED et al. No effects of gluten in patients with self-reported non-celiac gluten sensitivity after dietary reduction of fermentable, poorly absorbed, short-chain carbohydrates. Gastroenterology 2013;145:320-8.e1-3.
101. Gupta SC, Kismali G and Aggarwal BB. Curcumin, a component of turmeric: From farm to pharmacy. BioFactors 2013;39:2-13.
102. Ammon HP and Wahl MA. Pharmacology of curcuma longa. Planta Med 1991;57:1-7.
103. Ammon HP, Safayhi H, Mack T et al. Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 1993;38:113-9.
104. Patwardhan B, Warude D, Pushpangadan P et al. Ayurveda and traditional Chinese medicine: A comparative overview. Evid Based Complement Alternat Med 2005;2:465-73.
105. Shishodia S, Sethi G and Aggarwal BB. Curcumin: Getting back to the roots. Ann N Y Acad Sci 2005;1056:206-17.
106. Lubbad A, Oriowo MA and Khan I. Curcumin attenuates inflammation through inhibition of TLR-4 receptor in experimental colitis. Mol Cell Biochem 2009;322:127-35.
107. Billerey-Larmonier C, Uno JK, Larmonier N et al. Protective effects of dietary curcumin in mouse model of chemically induced colitis are strain dependent. InflammBowel Dis 2008;14:780-93.
108. Zhang M, Deng CS, Zheng JJ et al. Curcumin regulated shift from Th1 to Th2 in trinitrobenzene sulphonic acid-induced chronic colitis. Acta Pharmacol Sin 2006;27:1071-7.
109. Martelli L, Ragazzi E, di Mario F et al. A potential role for the vanilloid receptor TRPV1 in the therapeutic effect of curcumin in dinitrobenzene sulphonic acid-induced colitis in mice. Neurogastroenterol Motil 2007;19:668-74.
110. Deguchi Y, Andoh A, Inatomi O et al. Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci 2007;52:2993-8.
111. Ukil A, Maity S, Karmakar S et al. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003;139:209-18.
112. Sugimoto K, Hanai H, Tozawa K et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 2002;123:1912-22.
113. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J 2013;15:195-218.
114. Epstein J, Docena G, MacDonald TT et al. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br J Nutr 2010;103:824-32.
115. Larmonier CB, Midura-Kiela MT, Ramalingam R et al. Modulation of neutrophil motility by curcumin: Implications for inflammatory bowel disease. Inflamm Bowel Dis 2011;17:503-15.
116. Jobin C, Bradham CA, Russo MP et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999;163:3474-83.
117. Hanai H, Iida T, Takeuchi K et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:1502-6.
118. Lang A, Salomon N, Wu JC et al. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mildto-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol 2015;13:1444-9.e1.
119. Bundy R, Walker AF, Middleton RW et al. Turmeric extract may improve irritable bowel syndrome symptomology in otherwise healthy adults: A pilot study. J Altern Complement Med 2004;10:1015-8.
120. Ostad SN, Soodi M, Shariffzadeh M et al. The effect of fennel essential oil on uterine contraction as a model for dysmenorrhea, pharmacology and toxicology study. J Ethnopharmacol 2001;76:299-304.
121. Boskabady MH, Khatami A and Nazari A. Possible mechanism( s) for relaxant effects of Foeniculum vulgare on guinea pig tracheal chains. Pharmazie 2004;59:561-4.
122. Amjad H and Jafary HA. Foeniculum vulgare therapy in irritable bowel syndrome. Am J Gastroenterol 2000;95:2491.
123. Portincasa P, Bonfrate L, Scribano ML et al. Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome. J Gastrointestin Liver Dis 2016;25:151-7.